【摘要】 目的:比较齐拉西酮和利培酮治疗精神分裂症的疗效和安全性。方法:将84例精神分裂症患者随机分为两组,分别给予齐拉西酮和利培酮治疗8周。采用阳性症状与阴性症状量表(PANSS)评定临床疗效,治疗中出现的症状量表(TESS)评定不良反应。结果:齐拉西酮和利培酮治疗8周有效率分别为90.5%和92.9%,二药疗效的差异无显著性(P>0.05)。齐拉西酮组的不良反应发生率(38.1%)稍低于利培酮组(57.1%)。利培酮组锥体外系反应和内分泌改变的发生率均显著高于齐拉西酮组(P均<0.05)。但两药引起的不良反应一般为轻度或中度,患者耐受性较好。结论:齐拉西酮和利培酮对精神分裂症的疗效相当,但不良反应有所不同。更多还原

【Abstract】 Objective:To compare the efficacy and safety of ziprasidone and resperidone in the treatment of schizophrenia. Method:Eighty-four patients with schizophrenia were randomly assigned to two groups treated with ziprasidone or risperidone for 8 weeks.The positive and negative symptom scale(PANSS)and treatment emergent symptoms scale(TESS)were used to evaluate the efficacy and adverse effects before and at the end of 2nd,4th,8th weeks of treatment. Results:The total effective rates of ziprasidone and risperidone were 90.5% and 92.5% respectively after 8 weeks treatments.There was no significant difference between two groups(P>0.05).Incidence of adverse effects in ziprasidone group(38.1%) was lower than that in risperidone group(57.1%).The rates of extrapyramidal symptoms and endocrine change were significantly higher in risperidone group than those in ziprasidone group(P<0.05).But these side effects were not serious,and patients often had good tolerance for them. Conclusion:It is suggested that ziprasidone is an effective drug for schizophrenia,with light side effects.更多还原